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DopamineHuntington's disease (HD) is an inherited progressive neurodegenerative disorder associated with
involuntary abnormal movements (chorea), cognitive deﬁcits and psychiatric disturbances. The disease is
caused by an abnormal expansion of a CAG repeat located in exon 1 of the gene encoding the huntingtin
protein (Htt) that confers a toxic function to the protein. The most striking neuropathological change in HD is
the preferential loss of medium spiny GABAergic neurons in the striatum. The mechanisms underlying
striatal vulnerability in HD are unknown, but compelling evidence suggests that mitochondrial defects may
play a central role. Here we review recent ﬁndings supporting this hypothesis. Studies investigating the toxic
effects of mutant Htt in cell culture or animal models reveal mitochondrial changes including reduction of
Ca2+ buffering capacity, loss of membrane potential, and decreased expression of oxidative phosphorylation
(OXPHOS) enzymes. Striatal neurons may be particularly vulnerable to these defects. One hypothesis is that
neurotransmission systems such as dopamine and glutamate exacerbate mitochondrial defects in the
striatum. In particular, mitochondrial dysfunction facilitates impaired Ca2+ homeostasis linked to the
glutamate receptor-mediated excitotoxicity. Also dopamine receptors modulate mutant Htt toxicity, at least
in part through regulation of the expression of mitochondrial complex II. All these observations support the
hypothesis that mitochondria, acting as “sensors” of the neurochemical environment, play a central role in
striatal degeneration in HD.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Basic research has demonstrated that mitochondria are key actors
in cell survival by controlling energy metabolism, apoptosis pathways
and Ca2+ homeostasis [1–4]. The hypothesis that mitochondria could
play a role in neurodegenerative diseases arises from the observation
that mitochondrial defects and oxidative stress can be detected in
biological materials from patients with neurodegenerative conditions.
In addition, a number of cell biology experiments demonstrated that
mitochondria play an active role in the complex cascade of events
leading to cell demise in various models of neurodegenerative dis-
orders [5,6]. However, the question as to how mitochondrial defects
could be involved in the region speciﬁc pattern of degeneration is
unclear. It has been known for a long time that the striatum is extremely
sensitive to impairment in energy metabolism. Acute poisoning with
mitochondrial toxins (cyanide, sodium azide, and 3NP) is often asso-
ciated with striatal degeneration in man and laboratory animals [7,8].
Mitochondrial defects of genetic origins (e.g. mutation or deletion of
mitochondrial DNA or nuclear DNA) can lead to striatal degeneration
[7]. In Huntington's disease, recent studies have highlighted the par-ular Imaging Research Center
rama, F-92265 Fontenay-aux-
4 91 16.
llet).
ll rights reserved.ticular mechanisms that directly link mitochondrial defects with the
preferential vulnerability of the striatum, the brain region which
displays the earliest and most striking neuropathological changes in
patients.
2. Huntington's disease
2.1. Description
Huntington's disease (HD) is an autosomal-dominant inherited
neurodegenerative disorder of midlife onset caused by an abnormal
expansion of a CAG repeat located in the exon 1 of the gene encoding
for the Huntingtin protein (Htt) [9]. HD is characterized by
involuntary abnormal movements and postures (chorea, dyskinesia,
and dystonia) of the legs, trunk and face [10]. Speech disturbance
(dysarthria) is often seen. Other highly alienating symptoms consist
of mood, psychiatric disturbances and cognitive deﬁcits characterized
by a perseverative behaviour and impaired strategy and planiﬁcation.
With the progression of the disease, motor rigidity and dementia
predominate. The disease is fatal within 15−20 years after onset.
Although several cerebral regions show signs of neurodegeneration in
HD, the most striking neuropathological hallmark of this disorder is
the atrophy of the striatum as seen using post mortem histological
evaluation [11] or non-invasive brain magnetic resonance imaging
(MRI) [12–14]. Detection of pre-symptomatic patients (i.e. carrying
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the caudate and putamen [12–14]. This suggests that degenerative
events (cell shrinkage or loss) begin years before the occurrence of
clinical symptoms. The disease preferentially affects the GABAergic
medium size spiny neurons of the striatum that project to substantia
nigra reticulata and pallidum. Intriguingly, large cholinergic inter-
neurons andmedium size aspiny interneurons are preserved in theHD
striatum [15,16]. Cortical atrophy and early degeneration of the
hypothalamus are also important aspects of HD pathogenesis, and late
stageHDpatients showwidespreadbrain degeneration [17]. However,
the severity of striatal alterations is correlated with the degree of
motor, cognitive and psychiatric perturbations [18], suggesting that
striatal degeneration is an important aspect of HD physiopathology.
Many genetic models of HD have been generated in mice [19,20].
Transgenic mice express N-terminal fragments of different sizes, the
R6/2 mice which overexpress human exon 1 of the HD gene, have a
very strong behavioural phenotype with short life span and have been
the most studied model so far. Other transgenic models that express
the entire mutant human gene show a milder and more progressive
neurological phenotype (BACHD, YAC128Q). One transgenic ratmodel
expressing two thirds of the gene shows relatively mild degeneration
but develops motor and cognitive symptoms. The mouse models
that are genetically the most relevant to HD are the knock-in models
where a CAG expansion is inserted in the mouse homologue HD gene
(HDh111, HDh140, and HDh150). Excellent reviews have been re-
leased for a comprehensive view of the characteristics of the mouse
models that have been generated and are still currently used for
research [21–23]. The different types (summarized in Table 1) of the
mitochondrial defects which have been observed in these animal
models will be discussed below.2.2. Pathogenesis
Themutation induces both a loss of function and a gain of function.
Wild-type Htt plays an important role in cell survival by controlling
apoptosis pathways, regulating intracellular transport machinery,
vesicle trafﬁcking and secretion [24–26].Table 1
Main mitochondrial defects observed in genetic models of Huntington's disease.
Mitochondrial target/function Organism/model
Mitochondria membrane potential Primary culture of striatal neurons ex
Sensitivity of permeability transition pore to Ca2+ STHdhQ111/Q111 striatal cell line
Induction of permeability transition Recombinant N-terminal Htt fragmen
Ca2+ buffering capacity/handling Mitochondrial preparation from YAC
STHdhQ111/Q111 striatal cell line
Mitochondrial preparation from tg H
Striatal primary neurons from YAC12
Striatal primary neurons from HD150
Mitochondrial preparation from R6/2
Mitochondrial preparation from YAC
Mitochondrial preparation from HD1
Aconitase R6/2 brains
Pyruvate dehydrogenase R6/2 brains
Complex II/SDH activity Rat HD models using lentiviral vecto
Primary culture of striatal neurons ex
Neuro2A cells expressing Htt exon I
HeLa cells expressing Htt exon 1
Yeast expressing full length Htt
Expression of complex II subunits R6/1 tg mice
R6/2 tg mice (depending on age)
Primary culture of striatal neurons ex
Complex IV (COX) activity N171-82Q tg mice
Mitochondrial movement Cortical primary neurons expressing
Mitochondria transport machinery Cortical primary neurons
The left column indicates the mitochondrial targets/functions found defective in HD model
genetic models and corresponding references for further reading.The toxic functions acquired by mutant Htt may involve the full-
length Htt and the short N-terminus fragments produced by the
cleavage performed by different proteases, all of which have not been
identiﬁed yet. Cleavage by calpain [27–32] and caspases has been
demonstrated [33–35]. Experimental approaches have shown that the
N-terminus fragments ofmutantHtt recapitulate several aspects of the
full-lengthmutant protein's toxicity. Of interest, reducing the caspase-
6-dependent cleavage of full length mutant Htt markedly slows down
the progression of symptoms and neurodegeneration in a transgenic
mouse model of Huntington's disease [34]. However, it cannot be
totally ruled out that the C-terminal part of full length mutant Htt
could trigger toxic events. In a recently developed transgenic mouse
model of HD (bacterial artiﬁcial chromosome HD — BACHD) expres-
sing the full length human mutant gene, neuronal dysfunction starts
early while the accumulation of N-terminal Htt fragment is minimal
[36].
Abnormal transcription and transcription regulation have been
demonstrated [37,38]. Mutant Htt alters macromolecular complexes
regulating transcription. The mutation produces changes in protein−
protein interaction between Htt and transcription factors or co-factors
such as CBP, TAF4, CA150, Sp1, and p53, that can produce deleterious
downstream events. Mutant Htt could also lead to increased transglu-
taminase activity thus producing an abnormal covalent link between
proteins [39].
It has been shown that wild-type Htt regulates the expression of
BDNF by increasing REST/NRSF at the RE1/NRSE site located in the
BDNF promoter [40]. BDNF is an important factor contributing to
neuronal survival in the striatum. It is mainly synthesized in the cortical
neurons and delivered to the striatum through vesicles using axonal
transport [24]. Reduced BDNF levels in the striatum would render
medium size spiny neurons highly vulnerable.
Early axonal transport dysfunction and alteration of vesicle traf-
ﬁcking have been shown [41]. In particular impaired transport of
vesicles containing BDNF along the axon would further reduce the
delivery of BDNF to striatal cells [24]. Impaired axonal transport might
also affect organelle, including mitochondria localization (see below).
Protein misfolding, proteasome dysfunction [42,43], and reduction of
autophagy [44], likely play important roles in HD. Abnormal entry ofChange
(mutant/wt)
Ref.
pressing N-terminal Htt fragments Decreased [80,81]
Increased [78,104]
ts in vitro Increased [50,79]
72Q tg mouse brains Decreased [53]
Decreased [83]
D rat brains Decreased [77]
8Q tg mice Decreased [104]
Q knock-in mice Decreased [105]
tg mouse brains Increased [84]
128Q tg mouse brains Increased [105]
50Q, 111Q, 92Q and 50Q knock-in mouse brains ~ [84,105]
Decreased [70]
Decreased [70]
rs Decreased [95]
pressing N-terminal Htt fragments Decreased [81,117]
Decreased [97]
Decreased [97]
Decreased [98]
Decreased [95]
Decreased, increased, ~ [94]
pressing N-terminal Htt fragment Decreased [81,117]
Decreased [80]
a N-terminal fragment and full length Htt Decreased [100]
Decreased [101]
s (indicated in the second column). The table is not exhaustive. It lists main ﬁndings in
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[45,46]. Defective cytosolic Ca²+ buffering by mitochondria and
endoplasmic reticulum (ER) have been observed [47].
In the present review, we aim to provide an overview of how
mitochondrial dysfunction in HD could play a central role in cell
degeneration in HD [48,49]. How mitochondrial defects could
contribute to striatal degeneration is however debated. One important
point is that mutant Htt can interact with the outer mitochondrial
membrane [50–53]. Besides the direct interaction, the transcriptional
changes induced by mutant Htt and excitotoxicity could modify
some mitochondrial functions. The eventual energy failure would
render striatal cellsmore fragile, and eventually trigger the irreversible
cascade of events leading to cell death.
3. Preferential vulnerability of the striatum in human
mitochondrial disorders
It has been known for a long time that the striatum is extremely
vulnerable to the impairment in the OXPHOS system. Primary genetic
mitochondrial defects can lead to striatal degeneration and associated
motor and cognitive symptoms. For example deletions ormutations in
several mitochondrial genes may lead to Leigh syndrome, character-
ized by various degrees of basal ganglia damage, and possibly striatal
necrosis and, clinically, by choreoathetosis and dystonia. Point muta-
tions in mitochondrial genes coding for several subunits of complex I
(NADH:ubiquinone oxidoreductases) can lead to putaminal degener-
ation and dystonia, in associationwith other severe alterations such as
epilepsy, stroke and optic nerve atrophy. Mutations in mitochondrial
DNA encoded ND1 [54] genes produce Leber hereditary optic neurop-
athy and spastic dystonia. Mutations in ND3 [55] can also produce
Leigh syndrome.
More rarely, nuclear genes encoding for mitochondrial proteins or
assembly factors can lead to neurological abnormalities reminiscent of
Leigh syndrome. Defects in succinate oxidation [56] were associated
with bilateral striatal degeneration and dystonia. Loss of function in
the gene coding one of the succinate dehydrogenases (SDHA) deter-
mines Leigh syndrome [57]. A recent work reported striatal atrophy
resulting from homozygous point mutation in subunits VII of complex
III, ubiquinol−cytochrome c reductase [58].
Mutations in nuclear genes that encode for mitochondrial proteins
that are indirectly associated with OXPHOS can also lead to basal
ganglia dysfunction. For instance, mutation in the Myoﬁbrillogenesis
regulator-1 (MR-1) gene is the cause of the Paroxysmal non-
kinesigenic dyskinesia (PNKD) a rare autosomal-dominantmovement
disorder characterized by paroxystic episodes of dystonia and chorea
[59].
4. General mitochondrial and OXPHOS defects in HD patients and
HD models
4.1. Mitochondrial enzymes
Defects in the respiratory chain in HD have been observed in early
biochemical studies. Severe reduction in the activity of complex II/III
and milder reduction of complex IV were found in post mortem
samples of the caudate/putamen in HD patients.[60–64]. No changes
were observed in pre-symptomatic patients [65]. The cerebral cortex
showed minor changes in respiratory chain enzymes [61,63,66].
No change was observed in blood cells. Reduced activity of other
enzymes of oxidativemetabolism in the striatumwas also reported. In
particular massive loss of aconitase activity has been found in the
caudate (~90%), and putamen (~70%) [66,67]. Loss of the pyruvate
dehydrogenase complex was also shown [62,68]. Those defects were
observed in symptomatic patients with caudate/putamen atrophy.
Thus, whether they are a consequence of striatal degeneration, or they
play a pivotal role in it, remains to be determined.In a transgenic mouse model of HD (R6/2) with limited cell loss,
aconitase and pyruvate dehydrogenase have been found to be de-
creased to various extents [69]. It seems that in addition to presenting
reduced levels, many proteins are modiﬁed by oxidative stress in
these transgenic models [70]. Thus abnormalities in mitochondrial
proteins related to energy metabolism might not simply result from
the loss of mitochondria due to the neuronal loss. Experiments using
the mitochondrial toxin 3NP and recent studies on mitochondrial
complex II support the hypothesis that complex II dysfunction
(alteration), in conjunction with oxidative damage to mitochondrial
proteins might be causal in HD-linked striatal cell death (see below).
4.2. Brain examination using non-invasive methods
Other indications for energy metabolism problems in HD patients
were reported. In particular, early striatal hypometabolism was de-
tected in vivo using positron emission tomography and [18F]ﬂuoro-
deoxyglucose [7,71]. Increased lactate concentrationswere found in the
cortex of symptomatic HD patients using proton NMR spectroscopy
[72,73]. Lactate/pyruvate ratio was elevated in the CSF of HD patients
[74]. In one NMR study, half of the pre-symptomatic HD patients
examined showed increased lactate concentration in the striatum
[73]. In muscle, phosphorus NMR spectroscopy showed reduced ATP
production [75].
4.3. Mitochondrial membrane potential
Mitochondria isolated from cells expressing mutant Htt show
decreased membrane potential. As ﬁrst reported by Sawa et al., lym-
phoblasts derived from lymphocytes from HD patients showed
increased stress-induced apoptotic cell death [76]. When subjected
to apoptotic stress, lymphoblasts from patients displayed increased
mitochondrial membrane depolarisation as compared to control lym-
phocytes. This aggravated loss of potential was correlated with CAG
repeat expansion. Other studies also suggest an abnormal mitochon-
drial membrane potential in cell expressing mutant Htt. Others have
reported similar observations in lymphocytes/lymphoblasts [53]. In
neural cells, particularly in studies performed on clonal cells derived
from knock-in mice harbouring a pathologically expanded CAG repeat
tract (STHdhQ111/Q111), showed high sensitivity to Ca2+ induced
permeability transition [50]. This sensibility was conﬁrmed in many
recent studies, speciﬁcally when usingmitochondria isolated fromHD
transgenic rats [77]. STHdhQ111/Q111 cells also show higher
vulnerability to permeability transition when treated with the 3NP,
an effect that could be prevented by cyclosporine-A [78]. It has also
been demonstrated that recombinant mutant Htt (short N-terminal
fragment) could directly trigger loss of membrane potential and
permeability transition, likely through an interaction with the outer
mitochondrial membrane [50,79]. In situ studies using ﬂuorescent
dyes (JC-1, MitoTracker Red) that accumulate in themitochondria as a
function of the membrane potential conﬁrmed that neuronal cells
expressing mutant Htt could display reduced mitochondrial mem-
brane potential at rest [80,81].
4.4. Mitochondrial Ca2+ buffering capacity
IncreasedcytoplasmicCa2+ levels are toxic toneurons [82]. Impaired
Ca2+ homeostasis in HD might have different causes. Although it may
originate from various extra-mitochondrial origins (see below),
mechanisms related to mitochondrial dysfunction have received the
closest attention. The Ca2+ buffering capacity of cells expressingmutant
Htt can be reduced. This was ﬁrst shown by Panov et al. in lymphoblasts
derived from lymphocytes of HD patients [53]. Similarly, reduced Ca2+
loading capacity was found in the brains of YAC72Q mice [53]. Com-
pared to mitochondria from control cells (STHdhQ7/Q7), the mito-
chondria from clonal striatal cells with mutant Htt (STHdhQ111/Q111)
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treated with increasing Ca2+ loads and have a reduced capacity to take
up Ca2+ [83]. Isolated mitochondria from transgenic rats expressing
mutant Htt, show reduced rates of Ca2+ accumulation compared to
control rats [77]. However, other studies using knock-in HDmice (50Q,
92Q, 111Q and 150Q) did not show reduced brain mitochondrial Ca2+
loading capacity [84,105]. The latter was even found increased in
12 week old R6/2mice and 12 month old YAC128Q [84]. One possibility
is that changes in mitochondrial Ca2+ loading capacity are transient in
HDmice. Aging processes and cell substitutionmay occur in later stages
thus hiding the original defect.
5. Complex II defects in Huntington's disease
5.1. 3-Nitropropionic acid, a complex II inhibitor replicating many
aspects of Huntington's disease
In man the ingestion of the mitochondrial toxin 3-nitropropionic
acid (3NP) produces putaminal necrosis and delayed dyskinesias and
dystonia [85,86]. Systemic administration of 3NP produces in rats
[87,88] and in non-human primates [89] preferential degeneration in
the striatum, abnormal movements and frontal type cognitive deﬁcits
that are highly reminiscent of HD [8,48]. The 3NP models strongly
suggest that complex II defects detected in the striatum of HD patients
may participate to cell demise. Alongside the similar phenotype,
studies on 3NP toxicity also showed that mitochondrial defects and
mutant Htt toxicity share common pathogenic pathways, such as
impaired Ca2+ homeostasis, calpain and caspase activation, and
JNK activation [48]. However, 3NP does not produce transcriptional
changes that are comparable to those found in transgenic and knock-in
mice expressing mutant Htt [90,91]. The 3NP model should be con-
sidered as an excellent model to study the consequences of chronic
mitochondrial impairment and oxidative stress in vivo. As a model of
HD, it presents several limitations compared to transgenic animals
[48].
5.2. The SDH–complex II molecular evidence in HD
The main component of complex II is the enzyme succinate dehy-
drogenase (SDH) [92]. Complex II/SDH is composed of four nuclear-
encoded subunits: the 70 kDa Fp subunit that catalyses the oxidation
of succinate, the 30 kDa Ip subunit which transfers electrons to the
ubiquinone via its iron centers, and two small subunits (SDH-D and
SDH-C) that anchor the complex to the internal mitochondrial mem-
brane. Thus, complex II/SDH plays a central role in the respiratory
chain, in the tricarboxylic acid cycle and probably in the control of free
radical production [92,93].
The expression of the 30 kDa iron−sulfur (Ip) subunit and of the
70 kDa FAD (Fp) subunit was preferentially decreased in the striatum
of HD patients, compared with controls [81]. Other mitochondrial
proteins were examined including subunit IV of complex IV, alpha
subunit of the F1-ATPase, BclXL, a protein of the mitochondrial outer
membrane, and cytochrome c. None showed signiﬁcant changes in
the striatum of HD patients, suggesting that the defective expression
of complex II is not only the consequence of mitochondrial loss,
secondary to neuronal death. In the cortex and cerebellum there was
no decrease in SDH subunits [81].
Despite these observations, the possible role of complex II in HD is
questioned by the fact that many attempts to detect signiﬁcant
reduced enzymatic activity have failed in transgenic mouse models of
HD [71]. We also initially failed to ﬁnd reduced activity or expression
of complex II when studying R6/2 and N171-82Q mice at relatively
advanced symptomatic stages (Brouillet, Benchoua, personnel com-
munication). The reason for this is not totally understood but recent
ﬁndings strongly suggest that transient changes in SDH expression
might occur in transgenic HD mouse models. Careful longitudinalanalysis of R6/2 mice using well-controlled proteomics methods
showed expression changes of the Ip subunit [94]. A signiﬁcant 34%
decrease was seen in the 2 week old R6/2 mice. In the same model, a
50% increase was observed in 4 week old animals, before gross brain
atrophy and severe symptoms. Increased activity of many glycolysis
and OXPHOS enzymes was also observed in R6/2 mice at 4 weeks. At
6 weeks no changes were observed in the Ip subunit. At 8 weeks, in
contrast, Ip was again reduced by 37%.We also found reduced levels of
SDH Ip and Fp subunits in the striatum of R6/1 mice at 16 weeks of
age while at 32 weeks, changes were less pronounced [95]. Cortex
showed no change at either age. The apparent “wavy” changes in
Ip expression in R6/2 mice [94] may result from changes in cellular
composition of the brain tissue (i.e. neurons and astrocytes) especially
considering that reactive gliosis is a physiological phenomenon that
follows neuronal loss.
SDH activity was also reduced in the striatum of rats injected with
lentiviral vectors coding the 171 N-terminal part of Htt with 82
glutamines (Htt171-82Q) [95,96]. This was observed along with
reduced regional glucose consumption as assessed using quantitative
14C-2-deoxyglucose autoradiograph [95,96]. Depletion of activity was
in the 50% range at 8 weeks post infection in the region expressing
mutant, but not wild-type Htt fragment. Blocking mutant Htt using
siRNA strategy prevented the SDH and regional glucose consumption
reduction [95,96].
Only few studies report complex II changes in cells expressing
mutant Htt in culture. Complex II activity was found reduced in
Neuro2A and HeLa cells expressing Htt exon 1 [97]. Interestingly, in
yeast, mutant Htt can be cytotoxic through alteration of OXPHOS, in
particular reduced function and amount of mitochondrial respiratory
chain complex II+III [98]. The potential role of SDH/complex II in HD
has been examined in striatal neurons in primary culture using
infection with lentiviral vectors coding for the N-terminus part of
huntingtin (Htt) with either a pathological (Htt171-82Q) or physio-
logical (Htt171-19Q) polyglutamine tract [81]. A longitudinal bio-
chemical analysis after infection showed that, compared with Htt171-
19Q, expression of Htt171-82Q decreased the levels of Ip followed
by Fp subunits and reduction of the dehydrogenase activity of the
complex. Other mitochondrial proteins remained unchanged. Of
interest, the Htt171-82Q-induced loss of complex II did not result
from a decrease in mRNA levels. Thus reduction of SDH subunits may
be the result of a post-transcriptional problem. Overexpression of Ip
or Fp subunit restored complex II levels, blocked mitochondrial
dysfunction and prevented striatal cell death induced by Htt171-82Q
in primary neurons [81]. These results provide evidence that complex
II/SDH subunits are critical for the execution of mutant Htt-induced
cell death.
6. Possible mechanisms of mitochondrial dysfunction in HD
As discussed above, mutant Htt (N-terminal small fragments) can
possibly directly interact with the outer mitochondrial membrane.
This may destabilize mitochondrial membrane, and increase the
sensitivity of the mitochondrial permeability transition pore (mPTP)
to Ca2+ or other apoptotic stimuli. Mitochondrial changes that have
been hypothesised to play a role in other neurodegenerative diseases
could also be involved in HD (Fig. 1). In particular a shift in the fusion/
ﬁssion equilibrium might occur [99]. Reduced mitochondrial mobility
could reduce the incorporation of certain proteins leading to mito-
chondrial dysfunction [100]. An elegant study using live cell video
microscopy showed that aggregates impairmitochondrialmovements
along neuronal processes. Mitochondria may remain embedded in the
aggregate formations in the somato-dendritic compartment [101]. A
very interesting observation in this study is that full lengthmutant Htt,
more than the short N-terminal fragments, impairs mitochondrial
mobility. Radical oxygen species (ROS), whose production is thought
to be increased in HD patients and HD mouse models [67,71,102,103]
Fig. 1. Hypothetical mechanisms involving mitochondria in Huntington's disease pathogenesis. Mutant huntingtin (m-Htt) produces mitochondrial impairment through different
mechanisms. Mitochondria from HD patients and genetic models of HD show reduced membrane potential (ΔΨ), decreased Ca2+ buffering capacity, enhanced sensitivity to Ca2+-
induced permeability transition, and triggering of caspase-mediated apoptotic pathways involving caspases. In addition, m-Htt can produce preferential reduction of respiratory
chain enzymes, in particular complex II (SDH/II) and to a lesser extend cytochrome c oxido-reductase (IV). These mitochondrial defects may result from a direct interaction of m-Htt
with the outer membrane and/or indirect modiﬁcation of protein(s) expression linked to m-Htt-induced transcriptional changes. One important effect of m-Htt-induced
mitochondrial defects includes deregulation of cytosolic Ca2+ concentrations. In striatal cells, this could act in synergy with other m-Htt-induced modiﬁcation of Ca2+ homeostasis:
m-Htt increases the activation of the InsP3 receptor (IP3R) triggering Ca2+ release from the endoplasmic reticulum (ER) and enhances Ca2+ entry through NMDA receptors. In this
scenario, glutamate is a primary cause of Ca2+ transients during synaptic transmission, leading to Ca2+ deregulation and cell death (excitotoxicity) in cells expressing m-Htt. In
addition, the presence of dopamine could also render striatal cells more vulnerable to m-Htt toxicity. D1 receptors can exacerbate glutamate toxicity and D2 receptors might down
regulate expression of mitochondrial complex II. Mitochondrial defects can indirectly increase the activity of proteases that cleaves Htt, leading to enhanced production of N-
terminal Htt fragments. This would further exacerbate transcriptional defects which, through a vicious cycle, would further accentuate mitochondrial impairment.
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ing the vulnerability of the mPTP in the presence of Ca2+.
A cellular function that is severely altered in HD and could lead to
mitochondrial dysfunction is transcription. The vulnerability of mito-
chondria to Ca2+ loads and induction of permeability transition have
been recently studied by Oliveira and co-workers [104,105]. In this
accurate study, the authors show that mitochondria of STHdh111Q/
111Q cells derived from knock-in HD mice, as well as primary striatal
neurons from YAC128 mice, have reduced Ca2+ handling capacity,
when compared to control cells. These changes were prevented by
applying HDAC inhibitors [104]. This suggests that, at least in part,
mitochondrial defects are secondary to impairednuclear transcription.
Indeedmitochondrial biogenesis, and import ofmatrix andmembrane
proteins, are under the control of several nuclear transcription factors
and co-activators [106]. Reduced CREB-dependent transcription in HD
could have speciﬁc consequences on mitochondrial physiology. For
example, CREB regulates respiratory chain proteins (e.g. COX-IV and
cytochrome c) [107]. Recently, Ryu et al. demonstrated that CREB
could directly bind mtDNA on CRE binding sites, a process that is
stimulated bymitochondrial PKA [108]. Interestingly, the regulation of
CREB phosphorylation in mitochondria may involve Ca2+-dependent
phosphatase in neurons [109]. Thus, transcriptional problems pro-
duced by mutant Htt could lead to disruption of Ca2+ homeostasis,which in mitochondria may further reduce CREB-dependent expres-
sion of OXPHOSproteins, and result in energy failure and apoptotic cell
death.
It has been demonstrated that the accumulation of p53 plays a role
in mitochondrial dysfunction and HD-linked degeneration [80]. The
strong interaction between p53 and mutant Htt causes p53 accumu-
lation in the nucleus thus inducing p53 dependent transcription.
Reducing p53 activity using siRNA or gene deletion is neuroprotective
against mutant Htt. Knocking down p53 rescues striatal cells from
mutant Htt-inducedmitochondrial dysfunction (loss of mitochondrial
membrane potential and COX activity) [80]. It is currently unknown
whether the transcriptional effect of p53 plays a direct or indirect role
on cytosolic proteins that can regulate apoptosis such as Puma.
Another very interesting mechanism that has recently been
proposed to be involved in HD-linked striatal degeneration is the
PGC-1alpha pathway. Reduced expression of PGC-1alpha has been
reported in HDmodels [110,111]. PGC-1alpha is a nuclear co-activator
that plays a major role in mitochondrial biogenesis [110,111]. Mice
that are nullizygous for PGC-1alpha display abnormalities related to
energy metabolism and strikingly develop striatal lesions [112].
Increasing PGC-1alpha expression is neuroprotective against mutant
Htt toxicity and, on the contrary, when PGC1-alpha is knocked down,
neurons are highly vulnerable to mutant Htt toxicity in cell culture
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co-activator —PRC), also known to regulate important aspects of mito-
chondrial biogenesis and of respiratory enzymes, could be also involved
[113]. In line with this, it cannot be excluded that downstream of PGC-
1alpha, the nuclear respiratory factors, NRF-1 and NRF-2 [114] could
also participate in HD-linked mitochondrial dysfunction. The possible
mechanisms through which mutant Htt could impair mitochondrial
function is likely multifactorial and highly complex.
How couldmutantHtt produce the loss of complex II/SDH activity?
The loss of SDH subunitsmaynot be directly produced by transcription
regulation. The Fp SDH subunit possesses a CRE consensus sequence in
its promoter [115]. However it is unknown whether this site is active
or not. The mRNA expression for SDH-A and SDH-B is not markedly
reduced in the brain of HD patients [116], while there is a dramatic loss
of the proteins as assessed using western blots [81] and activity assay
[61,63]. Using cultured striatal neurons, we showed that expression
levels of mRNA coding for SDH subunits were not modiﬁed by mutant
Htt while protein expression and activity was reduced [81,117].
Mutant Htt could decrease the import of the Ip subunit into mito-
chondria, increase its degradation, or disturb its assembly into a
functional complex. Mutant Htt can bind to the outer mitochondrial
membrane [50,53]. This couldmodify themolecular machinery for the
SDH import. It is also possible that loss of membrane potential could
reduce or alter the incorporation of the FAD prosthetic group to the
Fp subunit and eventually induce complex II disassembly. Another
interesting possibility is related to the Ip protein mRNA structure
[81] which presents an un-translated region (UTR) named IRE (Iron
Responsive Element). Oxidative stress or imbalance in iron metabo-
lism couldmodify Ip expression through the binding of IRP-1 and IRP-2
[118].
7. Environmental factors underlying striatal vulnerability through
mitochondrial mechanisms
Obviously, reduced energy production, anomalies in the control of
apoptosis and reduced cytosolic Ca2+ handling capacity can affect cell
survival. Why is the striatum particularly vulnerable to mitochondrial
dysfunction in HD? The general hypothesis is that striatal vulnerabil-
ity to impairment in energy metabolism is caused by many factors. In
particular, neurotransmission systems which modulate activity of
striatal medium-sized spiny neurons could play a role.
7.1. Glutamate, excitotoxicity and mitochondria
Whereas purely mitochondrial changes (protein expression, mito-
chondrial membrane potential, and Ca2+ loading capacity) are not
always consistently observed in all experimental models (cell types
and mouse lines), one consistent observation is that in neurons,
mitochondrial Ca2+ handling is reduced, upon stimulation of gluta-
mate receptors in situ. The cause of this defect is not totally understood
but elegant studies try to explain how HD-induced mitochondrial
dysfunction could transform a physiological effect into an excitotoxic
one.
There are mainly two studiedmechanisms able to lead to impaired
Ca2+ homeostasis within striatal neurons: 1) increase in Ca2+ entry,
and 2) impaired Ca2+ sequestration/release into/from intracellular
stores. In fact the two mechanisms could co-exist and synergistically
exacerbate Ca2+ deregulation thus triggering cell death.
In addition, abnormal release of Ca2+ from ER likely exists in
neurons expressing mutant Htt. Mutant Htt facilitates activity of
type 1 inositol 1,4,5-trisphosphate receptors (InsP(3)R1) [119]. This is
an important aspect since, in the presence of impaired mitochon-
drial Ca2+ handling, and upon the pathologic stimulation of NMDA
receptors, the increased Ca2+ release from the ER could further in-
crease cytosolic Ca2+ up to excitotoxic levels and thus cause neuronal
apoptosis.Compelling evidence shows that abnormal activation of NMDA
receptors likely plays a role in HD pathogenesis [45,46,120,121].
Pioneering studies show that intrastriatal injection of NMDA receptor
agonists, including NMDA and quinolinate in laboratory animals
produces axon-sparing lesions which are reminiscent of HD [8]. In
particular, while medium-sized spiny neurons preferentially degener-
ate, interneurons (large cholinergic interneurons and medium size
aspiny GABAergic neurons expressing nNOS, somatostatin and neuro-
peptideY) are spared [122,123].More recently, several approaches have
shown that mutant Htt can directly modify NMDA-receptor function
through its interaction with PSD95 [124,125]. In particular, mutant Htt
increases the sensibility of neurons to excitotoxicity associated to
stimulation of NMDA receptors harbouring the NR2B subunits
[126,127]. Degeneration is exacerbated in mice with CAG expansion in
theHtt homologuegene (knock-inHdh150Q) and overexpressingNR2B
[128]. NMDA currents are increased in the striatum of transgenic mice
overexpressing full length Htt [124,127,129]. Decortication, which
removes glutamate afferents in the striatum, protects against striatal
degeneration in R6/2 mice [130]. Many electrophysiological data sup-
port the view that abnormal glutamatergic transmission in the cortico-
striatal pathway is a prominent aspect of striatal degeneration
(reviewed in [131]).
However, increased activation of NMDA receptors might not be a
prerequisite for excitotoxicity. Indeed, extracellular normal glutamate
concentrations can trigger excitotoxic cell death in neurons with
impaired energymetabolism [132]. In cell culture, pre-treatment with
3NP exacerbates the toxicity of low NMDA or glutamate concentra-
tions [133–135]. Three studies have demonstrated that this synergy
also operates in vivo by providing evidence that the size of striatal
lesions produced by NMDA is signiﬁcantly increased by injecting
malonate, a reversible complex II inhibitor, into the striatum [136] or
by systemic administration of 3NP [137,138]. Potentiation of QA
toxicity by inhibiting SDH/complex II with 3NP (in the 45% range)
is observed at non toxic doses 3NP. This effect is likely associated
with increased cytosolic Ca2+ concentrations in vivo. Intracellular Ca2+
imaging studies [132,137,139] showed that NMDA receptor activation
leads to higher cytoplasmic Ca2+ concentrations in 3NP-treated
cultured neurons and brain slices, as compared with untreated prepa-
rations. However, results obtained from 45Ca2+ experiments demon-
strated that, during NMDA receptor stimulation by an agonist, Ca2+
entry into primary striatal neurons is similarwith orwithout 3NP [137].
Thus the increased vulnerability of neurons to excitotoxicity when
complex II is deﬁcient is likely due to reducedmitochondrial capacity to
uptake cytosolic Ca2+ upon NMDA receptor stimulation [132,137,139].
A similar process may occur in neurons expressing mutant Htt and
subjected to NMDA receptor stimulation, despite the fact that reduction
in complex II is likely not a prerequisite. Complex II would further
aggravate the vulnerability of mitochondria to Ca2+ transients. Con-
sistent with this view, a study performed in the YAC128 mouse model
indicated that during the initial phase of NMDA toxicity, NMDA receptor
current and cytosolic Ca2+ loading are similar to thoseobserved inwild-
type striatal neurons [140]. However, NMDA receptor-mediated Ca2+
load triggered a more profound loss of mitochondrial membrane
potential in YAC128 neurons than in wild-type cells. After removal of
NMDA, YAC128 cells displayed a longer time to recover normal Ca2+
concentrations. This was attributed to higher sensitivity of YAC128
striatal cells to Ca2+ induced mitochondrial permeability transition
[140]. Oliveira and collaborators studied Ca2+ transients after NMDA
receptor stimulation in YAC128 striatal neurons in relation to the
modiﬁcation of mitochondrial membrane potential assessed using the
ﬂuorescentTMRM+probe [104,105]. They characterized thepatternsof
Ca2+ recovery after NMDA receptor stimulation in wild-type cells and
YAC128 striatal cells in culture. The proportion of neurons with delayed
recovery (i.e. initial cytosolic Ca2+ peak progressively returns to normal
after MK801 application) was signiﬁcantly higher in YAC128 neurons.
Striatal neurons prepared fromheterozygousHdh150Qknock-inmouse
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7.2. Dopamine and mitochondria
In addition to glutamate, other neurotransmission systems likely
play a role in HD pathogenesis [48,141,142]. In particular dopamine,
which is at high concentrations in the striatum compared to other
brain areas, might play an important role in the preferential vulner-
ability of the striatum in HD [143], possibly through a functional
interaction with mitochondria.
A number of in vivo and in vitro experiments showed that dopamine
contributes to striatal lesions produced by the mitochondrial toxin 3NP
(see for review [48]), suggesting thatdopaminecouldhavean impact on
mitochondrial function. Dopaminemay act as a co-factor inmutant Htt-
induced death in vitro, possibly through stimulation of autophagy [144].
However, autophagy is rather considered as neuroprotective in HD
pathogenesis [145]. Increased autophagy might lead to enhanced
mitochondria clearance in HD cells, and prevent the cells from entering
the apoptotic cascade. The production of free radicals following
dopamine oxidation [146] may also increase Htt toxicity [147].
However, direct support for the role for DA in HD comes from the
recent demonstration that the toxicity of the N-terminal fragments of
mutant Htt is potentiated by dopamine. Dopamine modiﬁes the forma-
tionofHtt-containingaggregates in primary striatal neurons transfected
with exon 1 of Htt gene and exacerbates mutant Htt-induced cell
death [147]. Of interest, this effect involves D2 receptor signalling, since
dopamine had this detrimental effect when neurons were prepared
from D2 receptor null mice [147]. In addition D2 antagonists signiﬁ-
cantly reduce the effects of dopamine. In vivo experiments also support
a role for dopamine and its receptors in HD pathogenesis: DAT
(dopamine transporter) knock-out (KO) mice crossed with a knock-in
transgenicmousemodel of HD showed enhancedmotor symptoms and
striatal degeneration induced by mutant Htt [148]. In YAC128 HDmice,
L-dopa treatment (which elevates dopamine concentrations) acceler-
ates striatal degeneration, whereas the neuroleptic tetrabenazine,
which reduces dopamine release, was neuroprotective [149]. Chronic
treatment with the D2 antagonist haloperidol signiﬁcantly reduces the
striatal toxicity of Htt171-82Q in vivo [150]. Stack et al. [130] showed
that 6OHDA-induced degeneration of the nigro-striatal dopaminergic
pathway prevents striatal degeneration in R6/2 HDmice.
We found that one of the underlying mechanisms of this “protoxic”
effect of dopamine in mutant Htt toxicity directly involves mitochon-
dria. Primary striatal neurons expressing Htt171-82Q were highly
vulnerable to dopamine when compared to normal neurons or neurons
expressing the wild-type fragments [117]. This was correlated with the
level of reduction of complex II/SDH activity. Indeed, incubation of
striatal neuronswith dopamine alone produced a signiﬁcant loss of SDH
activity and reduced expression of the subunits of the complex. Thiswas
related to a transient reduction of Ip and Fp complex II subunit mRNAs.
This dopamine-induced loss of complex II was mediated by D2
receptors. D2 receptor antagonists blocked the effect of dopamine and
D2 agonist replicated the effect of dopamine. The combined down
regulation of SDH/complex II by dopamine andmutant Htt leads to cell
death that can be blocked by overexpression of the Ip protein using
lentiviral vector-mediated gene transfer methods [117]. How this novel
mechanismcould play a role in vivo in the striatum is not yet elucidated.
However it could explain why the striatum is preferentially vulnerable
to the complex II inhibitor 3NP and mutant Htt toxicity.
8. Therapeutic strategies from theory to proof of concept
Theoretically, if mitochondrial defects found in HD patients and
HD models play a role in neuronal dysfunction and eventually
death, correcting these defects may provide beneﬁcial effects. Recent
ﬁndings support this hypothesis.Whereas gene transfer-based experiments recently led to the dis-
covery of potential therapeutic targets that could improve mitochon-
dria in HD (such as PGC-1alpha or the mitochondrial complex II),
preclinical studies are yet required to precisely determine whether it
is possible to modulate these systems in vivo. From a practical
perspective, the targeting of these complex systems will require
important and long-term developments. However, a few strategies
which were suggested many years ago have shown great promise in
preclinical and even clinical studies. Examples are given below.
In cells expressing mutant Htt, accumulation of p53 has been
showed to induce neuronal death. Reducing accumulation of p53
using RNA interference and the p53 inhibitor piﬁthrin-α suppresses
mutant Htt-induced mitochondrial depolarisation. Intraperitoneal
injection of piﬁthrin-α in 171-82Q HD transgenic mice restores levels
of complex IV activity to normal levels [80]. It can be speculated that
piﬁthrin-like drugs could be neuroprotective in patients.
The loss of mitochondrial Ca2+ handling observed in cell lines
derived from knock-in mouse model can be corrected by treatment
with the HDAC inhibitors trichostatin A or sodium butyrate, suggest-
ing that acting on transcription defects could correct some of
mitochondrial defects produced by mutant Htt [104]. Treatment
with HDAC inhibitors in mouse models of HD reduces striatal atrophy
and motor deﬁcits [151,152]. These beneﬁcial effects in mice could at
least in part involve amelioration of mitochondrial physiology.
Another approach consists in brain fuel supplementation. Themost
promising compound that could be efﬁcacious in increasing brain
energy metabolism is creatine, a compound produced endogenously
and acquired exogenously through diet [153]. Diet supplementation
with creatine (in the range of 600 mg/kg) in mice expressing the N-
terminal part of mutant huntingtin is neuroprotective. It extends life
span in transgenic mice, and reduces motor dysfunction and striatal
atrophy [154–156]. Creatine is well tolerated in patients [157]. It
seems that creatine produces an actual biological effect in HD patients
since blood levels of 8-hydroxy-2′-deoxyguanosine (8OH2′dG), a
biomarker of oxidative stress that is elevated in untreated HD patients
are near control levels in patients with creatine treatment. Ongoing
clinical trials may determine within few years whether creatine
treatment can slow the progression of the disease.
Production of ROS is likely increased in HD patients and HDmouse
models [67,71,102,103]. Reducing ROS production using compounds
with antioxidant properties has been tested in HD models [23]. For
example, ascorbate treatment in R6/2 mice ameliorates behavioural
deterioration [158]. The newly developed antioxidant BN82451
protects and extends survival in R6/2 mice [159]. The most debated
but still very promising compound is coenzyme Q10, which has
antioxidant properties and plays an important role in the transfer of
electrons in the respiratory chain [160]. Transgenic R6/2 mice treated
with coenzyme Q10 alone or in association with the NMDA receptor
antagonist remacemide show increased survival, attenuated weight
loss, improved motor performances, and reduced striatal atrophy
when compared with untreated transgenic mice [161,162]. Clinical
trials with relatively low dose showed no major protective effects,
suggesting that higher doses may be necessary.
9. Conclusion
Mitochondria likely play a key role in HD, although the exact
mechanisms involved are still under debate. Of interest, the striatum
might be particularly vulnerable to mitochondrial defects through
multiple mechanisms involving molecular factors which are selec-
tively present in this brain region. Amongst these factors, dopamine
and D2 receptors, which are present in high concentrations in the
striatum likely play a role in the selective degeneration of striatal
neurons expressing mutant Htt. Many other factors possibly deter-
mine striatal vulnerability and may directly regulate mitochondrial
homeostasis. Beyond a better understanding of these mechanisms,
59M. Damiano et al. / Biochimica et Biophysica Acta 1802 (2010) 52–61there is really an urgent need to ﬁnd an efﬁcacious therapeutic
strategy to slow disease progression. Many therapeutic strategies are
studied at a preclinical level and several clinical trials have been
carried out in HD patients. None have provided major beneﬁcial
effects. Continuing to precisely decipher the various ways by which
mitochondria are involved in HD pathogenesis will certainly help to
disclose new therapeutic strategies.
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